These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. [Analysis of therapeutic efficacy in 49 patients with advanced non-small cell cancer treated with gefitinib]. Zhang PL; Chen L Zhonghua Zhong Liu Za Zhi; 2007 Aug; 29(8):635-6. PubMed ID: 18210890 [No Abstract] [Full Text] [Related]
8. Afatinib (Gilotrif) for advanced non-small cell lung cancer. Med Lett Drugs Ther; 2015 May; 57(1469):e82-3. PubMed ID: 26039556 [No Abstract] [Full Text] [Related]
9. Osimertinib effective in EGFR T790M-positive lung cancer. Mayor S Lancet Oncol; 2017 Jan; 18(1):e9. PubMed ID: 27989430 [No Abstract] [Full Text] [Related]
11. Which Is Better EGFR-TKI Followed by Osimertinib: Afatinib or Gefitinib/Erlotinib? Tamiya M; Tamiya A; Suzuki H; Moriizumi K; Nakahama K; Taniguchi Y; Kunimasa K; Kimura M; Inoue T; Kuhara H; Nishino K; Hirashima T; Atagi S; Imamura F; Kumagai T Anticancer Res; 2019 Jul; 39(7):3923-3929. PubMed ID: 31262922 [TBL] [Abstract][Full Text] [Related]
12. Afatinib use in non-small cell lung cancer previously sensitive to epidermal growth factor receptor inhibitors: the United Kingdom Named Patient Programme. Khan F; Ottensmeier C; Popat S; Dua D; Dorey N; Ellis S; Szabo M; Upadhyay S; Califano R; Chan S; Lee L; Ali CW; Nicolson M; Bates AT; Button M; Chaudhuri A; Mulvenna P; Shaw HM; Danson SJ Eur J Cancer; 2014 Jul; 50(10):1717-1721. PubMed ID: 24726055 [TBL] [Abstract][Full Text] [Related]
13. Osimertinib in the treatment of patients with epidermal growth factor receptor T790M mutation-positive metastatic non-small cell lung cancer: clinical trial evidence and experience. Sullivan I; Planchard D Ther Adv Respir Dis; 2016 Dec; 10(6):549-565. PubMed ID: 27784815 [TBL] [Abstract][Full Text] [Related]
14. Liquid chromatography-tandem mass spectrometric assay for therapeutic drug monitoring of the EGFR inhibitors afatinib, erlotinib and osimertinib, the ALK inhibitor crizotinib and the VEGFR inhibitor nintedanib in human plasma from non-small cell lung cancer patients. Reis R; Labat L; Allard M; Boudou-Rouquette P; Chapron J; Bellesoeur A; Thomas-Schoemann A; Arrondeau J; Giraud F; Alexandre J; Vidal M; Goldwasser F; Blanchet B J Pharm Biomed Anal; 2018 Sep; 158():174-183. PubMed ID: 29883880 [TBL] [Abstract][Full Text] [Related]
16. Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC. Takeda M; Okamoto I; Tsurutani J; Oiso N; Kawada A; Nakagawa K Jpn J Clin Oncol; 2012 Jun; 42(6):528-33. PubMed ID: 22457323 [TBL] [Abstract][Full Text] [Related]
17. [Successful Treatment of Non-Small Cell Lung Cancer with Afatinib after Gefitinib-Induced Hepatotoxicity]. Imai A; Hachiya T; Ikuyama Y; Sonehara K; Fujimori A; Shiba H; Atobe O Gan To Kagaku Ryoho; 2016 Jan; 43(1):91-4. PubMed ID: 26809532 [TBL] [Abstract][Full Text] [Related]
18. Safety of gefitinib in non-small cell lung cancer treatment. Hsiue EH; Lee JH; Lin CC; Yang JC Expert Opin Drug Saf; 2016 Jul; 15(7):993-1000. PubMed ID: 27212579 [TBL] [Abstract][Full Text] [Related]
19. Experience with afatinib in patients with non-small cell lung cancer progressing after clinical benefit from gefitinib and erlotinib. Schuler M; Fischer JR; Grohé C; Gütz S; Thomas M; Kimmich M; Schneider CP; Laack E; Märten A; Oncologist; 2014 Oct; 19(10):1100-9. PubMed ID: 25232040 [TBL] [Abstract][Full Text] [Related]
20. Afatinib: A first-line treatment for selected patients with metastatic non-small-cell lung cancer. Engle JA; Kolesar JM Am J Health Syst Pharm; 2014 Nov; 71(22):1933-8. PubMed ID: 25349236 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]